Search
for
Sort by
Research 601–630 of 638
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
- Industry updates in advanced therapy medicinal products and regenerative medicine – March 2026
- Combination Therapy for Extensive Tumoral Calcinosis in Juvenile Dermatomyositis
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO ‐2b/3 and ALLEGRO ‐ LT Clinical Studies for Alopecia Areata
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Research progress in the treatment of non-scarring alopecia: mechanism and treatment
- From the Cochrane Library: Interventions for Nail Psoriasis
- Hair
- Refractory Myasthenia Gravis and Concurrent Alopecia Areata Postthymectomy With Improvements After Cortisone Taper: A Case Report
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Assessment of Multidimensional Health Care Parameters Among Adults in Japan for Developing a Virtual Human Generative Model: Protocol for a Cross-sectional Study
- Atypical Presentation of Lichen Planopilaris: Presentation of Two Cases and Review
- Selection signatures for fiber production in commercial species: A review
- Post-Acute COVID-19 Sequelae – ‘COVID Long Hauler’
- Autosomal recessive woolly hair syndrome: a series of eight patients in an Indian population
- #6180 OXALATE NEPHROPATHY SECONDARY TO ENTERIC HYPEROXALURIA: A RARE CAUSE OF END STAGE RENAL FAILURE – A REPORT OF 2 CASES
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Clinical Manifestations of Dermatomyositis
- Baricitinib: A Review in Severe Alopecia Areata
- Visual Improvement in a Child With Periorbital Plexiform Neurofibroma Treated With Selumetinib: Case Report and Literature Review
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
- Hair loss and cardiovascular health
- 494 Epidermolysis bullosa pruriginosa, muscular dystrophy, and immune-mediated myasthenia gravis in a patient with homozygous nonsense PLEC mutation
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study